Blueprint Medicines Co. (NASDAQ:BPMC) Stock Position Lowered by Captrust Financial Advisors

Captrust Financial Advisors lowered its stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 53.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 8,331 shares of the biotechnology company's stock after selling 9,573 shares during the period. Captrust Financial Advisors' holdings in Blueprint Medicines were worth $727,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Avoro Capital Advisors LLC bought a new stake in shares of Blueprint Medicines during the 4th quarter valued at about $103,356,000. Norges Bank bought a new stake in shares of Blueprint Medicines during the 4th quarter valued at about $62,028,000. Jennison Associates LLC bought a new stake in shares of Blueprint Medicines during the 4th quarter valued at about $31,417,000. Rock Springs Capital Management LP grew its position in shares of Blueprint Medicines by 42.7% during the 4th quarter. Rock Springs Capital Management LP now owns 1,096,899 shares of the biotechnology company's stock valued at $95,672,000 after buying an additional 328,123 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in shares of Blueprint Medicines by 8.0% during the 4th quarter. Wellington Management Group LLP now owns 4,281,364 shares of the biotechnology company's stock valued at $373,421,000 after buying an additional 316,754 shares during the last quarter.

Blueprint Medicines Price Performance

Shares of NASDAQ:BPMC traded up $1.16 during trading on Friday, reaching $101.50. The company had a trading volume of 353,347 shares, compared to its average volume of 779,890. The firm's fifty day moving average is $90.77 and its 200 day moving average is $94.66. The firm has a market capitalization of $6.56 billion, a PE ratio of -93.98 and a beta of 0.83. Blueprint Medicines Co. has a twelve month low of $73.04 and a twelve month high of $121.90. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.32). The business had revenue of $149.41 million for the quarter, compared to the consensus estimate of $158.31 million. Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. The company's quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.40 earnings per share. On average, equities analysts forecast that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on BPMC. HC Wainwright reaffirmed a "buy" rating and set a $135.00 price objective on shares of Blueprint Medicines in a research report on Friday, May 2nd. Wall Street Zen raised shares of Blueprint Medicines from a "sell" rating to a "hold" rating in a research note on Friday, May 2nd. Scotiabank began coverage on shares of Blueprint Medicines in a research note on Friday, March 7th. They set a "sector outperform" rating and a $150.00 target price for the company. Jefferies Financial Group began coverage on shares of Blueprint Medicines in a research note on Monday, March 17th. They set a "buy" rating and a $135.00 target price for the company. Finally, JMP Securities reissued a "market outperform" rating and set a $125.00 target price on shares of Blueprint Medicines in a research note on Friday, February 14th. Five research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Blueprint Medicines currently has a consensus rating of "Moderate Buy" and a consensus price target of $126.56.

Insider Buying and Selling

In related news, COO Christina Rossi sold 2,274 shares of the company's stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $101.75, for a total value of $231,379.50. Following the completion of the sale, the chief operating officer now owns 66,992 shares in the company, valued at approximately $6,816,436. This represents a 3.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ariel Hurley sold 3,203 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $92.62, for a total transaction of $296,661.86. Following the completion of the sale, the insider now owns 18,270 shares of the company's stock, valued at approximately $1,692,167.40. This trade represents a 14.92% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 12,777 shares of company stock worth $1,256,490. Corporate insiders own 4.21% of the company's stock.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.